Adicet Bio, Inc. (NASDAQ: ACET) Stock Competitors & Peer Comparison
See ACET's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ACET and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ACET | $9.23 | +0.54% | 83.5M | -0.78 | -$11.45 | N/A |
| VRTX | $520.71 | +2.43% | 129.6B | 26.83 | $19.03 | N/A |
| REGN | $810.99 | +3.33% | 82.2B | 17.49 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| MRNA | $183.50 | +19.12% | 68.6B | -21.22 | -$8.15 | N/A |
| ARGX | $973.06 | -1.74% | 61.5B | 35.63 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $192.70 | +0.92% | 41B | -21.85 | -$8.82 | N/A |
| RVMDW | $9.97 | +3.37% | 39.3B | -1.13 | -$8.82 | N/A |
| ONC | $367.13 | +4.64% | 39.1B | 64.38 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ACET vs VRTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, VRTX has a market cap of 129.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while VRTX trades at $520.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas VRTX's P/E ratio is 26.83. In terms of profitability, ACET's ROE is -0.75%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ACET is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ACET vs REGN Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, REGN has a market cap of 82.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while REGN trades at $810.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas REGN's P/E ratio is 17.49. In terms of profitability, ACET's ROE is -0.75%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ACET is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ACET.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ACET vs VRNA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ACET's ROE is -0.75%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ACET is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ACET.Check VRNA's competition here
Moderna, Inc. (NASDAQ: MRNA)
ACET vs MRNA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MRNA has a market cap of 68.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MRNA trades at $183.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MRNA's P/E ratio is -21.22. In terms of profitability, ACET's ROE is -0.75%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ACET is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ACET.Check MRNA's competition here
argenx SE (NASDAQ: ARGX)
ACET vs ARGX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ARGX has a market cap of 61.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ARGX trades at $973.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ARGX's P/E ratio is 35.63. In terms of profitability, ACET's ROE is -0.75%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ACET is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ACET vs SGEN Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ACET's ROE is -0.75%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ACET is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ACET.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ACET vs RVMD Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RVMD trades at $192.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RVMD's P/E ratio is -21.85. In terms of profitability, ACET's ROE is -0.75%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ACET is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ACET.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ACET vs RVMDW Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RVMDW has a market cap of 39.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RVMDW trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RVMDW's P/E ratio is -1.13. In terms of profitability, ACET's ROE is -0.75%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ACET is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ACET.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
ACET vs ONC Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ONC has a market cap of 39.1B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ONC trades at $367.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ONC's P/E ratio is 64.38. In terms of profitability, ACET's ROE is -0.75%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ACET is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ACET vs ALNY Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ALNY has a market cap of 32.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ALNY trades at $254.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ALNY's P/E ratio is 44.02. In terms of profitability, ACET's ROE is -0.75%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ACET is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ACET vs ROIV Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ROIV has a market cap of 28.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ROIV trades at $38.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ROIV's P/E ratio is -37.09. In terms of profitability, ACET's ROE is -0.75%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ACET is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
ACET vs INSM Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, INSM has a market cap of 26.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while INSM trades at $121.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas INSM's P/E ratio is -29.44. In terms of profitability, ACET's ROE is -0.75%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ACET is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ACET.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
ACET vs INCY Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, INCY has a market cap of 25.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while INCY trades at $127.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas INCY's P/E ratio is 16.75. In terms of profitability, ACET's ROE is -0.75%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ACET is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ACET.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
ACET vs BNTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, BNTX has a market cap of 24.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while BNTX trades at $101.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas BNTX's P/E ratio is -12.71. In terms of profitability, ACET's ROE is -0.75%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ACET is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
ACET vs GMAB Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while GMAB trades at $35.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas GMAB's P/E ratio is 26.14. In terms of profitability, ACET's ROE is -0.75%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ACET is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ACET.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ACET vs UTHR Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, UTHR has a market cap of 20.9B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while UTHR trades at $498.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas UTHR's P/E ratio is 17.64. In terms of profitability, ACET's ROE is -0.75%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ACET is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ACET.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ACET vs BGNE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ACET's ROE is -0.75%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ACET is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ACET.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ACET vs DNA-WT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ACET's ROE is -0.75%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ACET is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ACET.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ACET vs JAZZ Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while JAZZ trades at $240.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, ACET's ROE is -0.75%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ACET is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ACET.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ACET vs ASND Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ASND trades at $236.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ASND's P/E ratio is -98.18. In terms of profitability, ACET's ROE is -0.75%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ACET is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ACET vs NBIX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while NBIX trades at $142.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas NBIX's P/E ratio is 20.80. In terms of profitability, ACET's ROE is -0.75%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ACET is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ACET vs EXEL Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, EXEL has a market cap of 14.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while EXEL trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas EXEL's P/E ratio is 16.35. In terms of profitability, ACET's ROE is -0.75%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ACET is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ACET.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ACET vs SMMT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while SMMT trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas SMMT's P/E ratio is -15.09. In terms of profitability, ACET's ROE is -0.75%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ACET is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ACET.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ACET vs HALO Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while HALO trades at $114.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas HALO's P/E ratio is 20.79. In terms of profitability, ACET's ROE is -0.75%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ACET is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ACET.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ACET vs BBIO Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while BBIO trades at $69.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas BBIO's P/E ratio is -17.80. In terms of profitability, ACET's ROE is -0.75%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ACET is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ACET.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ACET vs KRTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ACET's ROE is -0.75%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ACET is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ACET vs BMRN Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas BMRN's P/E ratio is 30.80. In terms of profitability, ACET's ROE is -0.75%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ACET is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ACET.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ACET vs MDGL Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MDGL trades at $523.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MDGL's P/E ratio is -40.78. In terms of profitability, ACET's ROE is -0.75%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ACET is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ACET.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ACET vs TECH Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TECH trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TECH's P/E ratio is 37.36. In terms of profitability, ACET's ROE is -0.75%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ACET is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ACET.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ACET vs RNAM Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ACET's ROE is -0.75%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ACET is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ACET.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ACET vs AXSM Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while AXSM trades at $204.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas AXSM's P/E ratio is -53.65. In terms of profitability, ACET's ROE is -0.75%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ACET is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ACET.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ACET vs TWST Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TWST has a market cap of 10.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TWST trades at $167.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TWST's P/E ratio is -74.69. In terms of profitability, ACET's ROE is -0.75%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ACET is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ACET.Check TWST's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ACET vs TXG Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TXG has a market cap of 10B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TXG trades at $80.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TXG's P/E ratio is -134.07. In terms of profitability, ACET's ROE is -0.75%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ACET is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ACET.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ACET vs KRYS Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while KRYS trades at $350.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas KRYS's P/E ratio is 41.84. In terms of profitability, ACET's ROE is -0.75%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ACET is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ACET.Check KRYS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ACET vs ARWR Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ARWR has a market cap of 9.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ARWR trades at $71.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ARWR's P/E ratio is -30.57. In terms of profitability, ACET's ROE is -0.75%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ACET is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ACET vs KYMR Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while KYMR trades at $121.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas KYMR's P/E ratio is -36.77. In terms of profitability, ACET's ROE is -0.75%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ACET is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ACET.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ACET vs RXDX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ACET's ROE is -0.75%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ACET is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ACET vs PTGX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while PTGX trades at $145.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas PTGX's P/E ratio is 140.76. In terms of profitability, ACET's ROE is -0.75%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ACET is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ACET vs NUVL Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ACET's ROE is -0.75%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ACET is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ACET.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ACET vs CRNX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ACET's ROE is -0.75%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ACET is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ACET vs IBRX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while IBRX trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas IBRX's P/E ratio is -8.71. In terms of profitability, ACET's ROE is -0.75%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ACET is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ACET vs TGTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TGTX trades at $58.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TGTX's P/E ratio is 20.71. In terms of profitability, ACET's ROE is -0.75%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ACET is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check TGTX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ACET vs IMGN Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ACET's ROE is -0.75%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ACET is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ACET.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ACET vs CAI Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CAI trades at $31.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CAI's P/E ratio is 86.12. In terms of profitability, ACET's ROE is -0.75%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ACET is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ACET vs PCVX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while PCVX trades at $59.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas PCVX's P/E ratio is -7.72. In terms of profitability, ACET's ROE is -0.75%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ACET is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check PCVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ACET vs CYTK Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CYTK trades at $67.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CYTK's P/E ratio is -9.36. In terms of profitability, ACET's ROE is -0.75%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ACET is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CYTK's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ACET vs BPMC Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ACET's ROE is -0.75%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ACET is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ACET.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ACET vs APGE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas APGE's P/E ratio is -31.19. In terms of profitability, ACET's ROE is -0.75%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ACET is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ACET.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ACET vs PRAX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while PRAX trades at $299.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas PRAX's P/E ratio is -23.11. In terms of profitability, ACET's ROE is -0.75%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ACET is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ACET vs CERE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CERE's P/E ratio is -16.47. In terms of profitability, ACET's ROE is -0.75%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ACET is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ACET vs SYRE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, SYRE has a market cap of 8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while SYRE trades at $91.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas SYRE's P/E ratio is -47.19. In terms of profitability, ACET's ROE is -0.75%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ACET is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ACET.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ACET vs IMVT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while IMVT trades at $37.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas IMVT's P/E ratio is -13.18. In terms of profitability, ACET's ROE is -0.75%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ACET is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ACET.Check IMVT's competition here
Abivax S.A. (NASDAQ: ABVX)
ACET vs ABVX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ABVX trades at $98.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ABVX's P/E ratio is -19.69. In terms of profitability, ACET's ROE is -0.75%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ACET is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ACET vs IONS Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while IONS trades at $46.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas IONS's P/E ratio is -13.73. In terms of profitability, ACET's ROE is -0.75%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ACET is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ACET.Check IONS's competition here
Metsera, Inc. (NASDAQ: MTSR)
ACET vs MTSR Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ACET's ROE is -0.75%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ACET is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ACET.Check MTSR's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ACET vs BLTE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while BLTE trades at $175.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas BLTE's P/E ratio is -92.73. In terms of profitability, ACET's ROE is -0.75%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ACET is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ACET.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
ACET vs CGON Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CGON trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CGON's P/E ratio is -29.09. In terms of profitability, ACET's ROE is -0.75%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ACET is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ACET.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
ACET vs MRUS Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ACET's ROE is -0.75%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ACET is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ACET.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ACET vs RYTM Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RYTM trades at $99.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RYTM's P/E ratio is -31.78. In terms of profitability, ACET's ROE is -0.75%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ACET is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ACET.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ACET vs ACLX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ACET's ROE is -0.75%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ACET is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ACET vs RETA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RETA's P/E ratio is -66.29. In terms of profitability, ACET's ROE is -0.75%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ACET is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ACET.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ACET vs CNTA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ACET's ROE is -0.75%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ACET is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ACET vs TVTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TVTX trades at $60.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TVTX's P/E ratio is -139.69. In terms of profitability, ACET's ROE is -0.75%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ACET is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check TVTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ACET vs LGND Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while LGND trades at $297.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas LGND's P/E ratio is 31.84. In terms of profitability, ACET's ROE is -0.75%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ACET is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ACET.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ACET vs SRRK Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while SRRK trades at $51.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas SRRK's P/E ratio is -13.96. In terms of profitability, ACET's ROE is -0.75%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ACET is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ACET.Check SRRK's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ACET vs ORKA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ORKA trades at $94.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ORKA's P/E ratio is -48.13. In terms of profitability, ACET's ROE is -0.75%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ACET is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ORKA's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ACET vs CRSP Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CRSP trades at $59.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CRSP's P/E ratio is -12.25. In terms of profitability, ACET's ROE is -0.75%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ACET is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ACET.Check CRSP's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ACET vs CDTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ACET's ROE is -0.75%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ACET is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ACET vs MIRM Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MIRM trades at $90.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MIRM's P/E ratio is -6.32. In terms of profitability, ACET's ROE is -0.75%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ACET is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ACET.Check MIRM's competition here
Abcam plc (NASDAQ: ABCM)
ACET vs ABCM Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ACET's ROE is -0.75%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ACET is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ACET vs ISEE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ACET's ROE is -0.75%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ACET is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ACET vs COGT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while COGT trades at $32.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas COGT's P/E ratio is -15.17. In terms of profitability, ACET's ROE is -0.75%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ACET is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ACET.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ACET vs PTCT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while PTCT trades at $66.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas PTCT's P/E ratio is -28.01. In terms of profitability, ACET's ROE is -0.75%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ACET is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ACET.Check PTCT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ACET vs DNTH Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while DNTH trades at $97.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas DNTH's P/E ratio is -23.25. In terms of profitability, ACET's ROE is -0.75%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ACET is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ACET.Check DNTH's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ACET vs APLS Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas APLS's P/E ratio is 38.35. In terms of profitability, ACET's ROE is -0.75%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ACET is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ACET.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
ACET vs ERAS Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ERAS trades at $15.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ERAS's P/E ratio is -16.17. In terms of profitability, ACET's ROE is -0.75%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ACET is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ERAS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ACET vs DFTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while DFTX trades at $39.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas DFTX's P/E ratio is N/A. In terms of profitability, ACET's ROE is -0.75%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ACET is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check DFTX's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ACET vs EWTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while EWTX trades at $45.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas EWTX's P/E ratio is -24.13. In terms of profitability, ACET's ROE is -0.75%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ACET is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ACET.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ACET vs TERN Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TERN's P/E ratio is -51.41. In terms of profitability, ACET's ROE is -0.75%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ACET is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ACET.Check TERN's competition here
Veradermics, Incorporated (NYSE: MANE)
ACET vs MANE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MANE trades at $117.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MANE's P/E ratio is -35.94. In terms of profitability, ACET's ROE is -0.75%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ACET is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ACET.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ACET vs FOLD Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ACET's ROE is -0.75%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ACET is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ACET.Check FOLD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ACET vs IOVA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, IOVA has a market cap of 4.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while IOVA trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas IOVA's P/E ratio is -13.96. In terms of profitability, ACET's ROE is -0.75%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ACET is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ACET.Check IOVA's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ACET vs ACAD Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ACAD trades at $26.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ACAD's P/E ratio is 11.89. In terms of profitability, ACET's ROE is -0.75%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ACET is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ACAD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ACET vs AKRO Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ACET's ROE is -0.75%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ACET is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ACET.Check AKRO's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ACET vs ADPT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ADPT trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ADPT's P/E ratio is -67.95. In terms of profitability, ACET's ROE is -0.75%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ACET is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ACET vs ALPN Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ACET's ROE is -0.75%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ACET is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ACET.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ACET vs PBLS Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while PBLS trades at $38.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas PBLS's P/E ratio is -19.64. In terms of profitability, ACET's ROE is -0.75%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ACET is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ACET.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
ACET vs OPT Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas OPT's P/E ratio is -1.52. In terms of profitability, ACET's ROE is -0.75%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ACET is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ACET.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ACET vs PRTC Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ACET's ROE is -0.75%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ACET is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ACET.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ACET vs MRTX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ACET's ROE is -0.75%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ACET is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
ACET vs CELC Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CELC trades at $84.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CELC's P/E ratio is -19.53. In terms of profitability, ACET's ROE is -0.75%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ACET is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ACET vs RLAY Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RLAY trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RLAY's P/E ratio is -11.59. In terms of profitability, ACET's ROE is -0.75%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ACET is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ACET.Check RLAY's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ACET vs ABCL Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while ABCL trades at $12.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas ABCL's P/E ratio is -23.44. In terms of profitability, ACET's ROE is -0.75%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ACET is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for ACET.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ACET vs CPRX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ACET's ROE is -0.75%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ACET is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CPRX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ACET vs TLX Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while TLX trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas TLX's P/E ratio is 118.06. In terms of profitability, ACET's ROE is -0.75%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ACET is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ACET.Check TLX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ACET vs XENE Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while XENE trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas XENE's P/E ratio is -8.30. In terms of profitability, ACET's ROE is -0.75%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ACET is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ACET.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ACET vs RYZB Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ACET's ROE is -0.75%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ACET is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ACET.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ACET vs CBAY Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ACET's ROE is -0.75%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ACET is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ACET.Check CBAY's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
ACET vs IDYA Comparison September 2026
Adicet Bio, Inc. (NASDAQ: ACET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ACET stands at 83.5M. In comparison, IDYA has a market cap of 3.7B. Regarding current trading prices, ACET is priced at $9.23 on the NASDAQ, while IDYA trades at $39.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ACET currently has a P/E ratio of -0.78, whereas IDYA's P/E ratio is -20.03. In terms of profitability, ACET's ROE is -0.75%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, ACET is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for ACET.Check IDYA's competition here